Wall Street's biggest bull sees tech and AI driving an 11% stock gain, fueled by strong fundamentals, M&A activity, and ...

In the recent 13F filings, Pfizer has seen a mix of investment adjustments from 11 institutions, reflecting a divided market ...

Intel is scheduled to report second-quarter results after the closing bell Thursday, with analysts tracked by Visible Alpha ...

Oppenheimer initiated coverage of the buy now, pay later firm Monday, issuing an "outperform" rating for Affirm stock.

While Pfizer's dividend yield is clearly much higher than Merck's, both have relatively attractive yields today. And you ...

Pfizer Inc. (NYSE:PFE) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. Pfizer Inc. (NYSE:PFE) hasn’t performed well in recent years, with its stock declining more than 26% over ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

Accenture downgraded to neutral amid soft bookings, weak guidance, and demand uncertainty. See here to know more on ACN stock ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Arexvy is currently approved for use in all individuals aged 60 and older, as well as for high-risk individuals aged 50-59.

PBF Energy Inc. (NYSE: PBF) is one of the 10 Energy Stocks with Insider Buying in 2025. Despite the successful completion of ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...